Disseminated intravascular coagulation
diseaseOn this page
Also known as coagulation (DIC), disseminated intravascularconsumptive coagulopathydefibrination syndromeDICDIC, disseminated intravascular coagulationdiffuse or disseminated intravascular coagulationdisseminated intravascular coagulation (DIC)intravascular coagulation (DIC), disseminated
Summary
Disseminated intravascular coagulation (MONDO:0001243) is a disease and 28 clinical trials. Top therapeutic interventions include antithrombin alfa, heparin sodium, and sodium chloride. A subtype of thrombophilia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 28
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | disseminated intravascular coagulation |
| Mondo ID | MONDO:0001243 |
| MeSH | D004211 |
| DOID | DOID:11247 |
| ICD-10-CM | D65 |
| ICD-11 | 1622289887 |
| NCIT | C2992 |
| SNOMED CT | 67406007 |
| UMLS | C0012739 |
| MedGen | 41620 |
| GARD | 0022908 |
| Is cancer (heuristic) | no |
Also known as: coagulation (DIC), disseminated intravascular · consumptive coagulopathy · defibrination syndrome · DIC · DIC, disseminated intravascular coagulation · diffuse or disseminated intravascular coagulation · disseminated intravascular coagulation · disseminated intravascular coagulation (DIC) · intravascular coagulation (DIC), disseminated
Disease family
This is a subtype of thrombophilia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood coagulation disease › thrombophilia › disseminated intravascular coagulation
Related subtypes (3): protein S deficiency, thrombotic thrombocytopenic purpura, inherited thrombophilia
Subtypes (2): purpura fulminans, disseminated intravascular coagulation in newborn
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Antithrombin Alfa | Phase 3 (in late-stage trials) |
| Antithrombin Iii Human | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aspirin, Ergocalciferol.
Clinical trials & evidence
Clinical trials
Clinical trials: 28.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 19 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01704001 | PHASE4 | COMPLETED | Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment |
| NCT01384396 | PHASE3 | COMPLETED | A Clinical Study of KW-3357 in Patients With DIC |
| NCT01384409 | PHASE3 | TERMINATED | A Phase 3 Clinical Study of KW-3357 in Patients With DIC |
| NCT01384903 | PHASE3 | COMPLETED | An Open-label Study of KW-3357 |
| NCT02654561 | PHASE3 | UNKNOWN | Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation |
| NCT00487656 | PHASE2 | COMPLETED | Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation |
| NCT00506519 | PHASE2 | TERMINATED | Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis |
| NCT04363840 | PHASE2 | WITHDRAWN | The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations |
| NCT04547153 | PHASE2 | COMPLETED | Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC |
| NCT06363149 | Not specified | RECRUITING | Disseminated Intravascular Coagulation (DIC) Score and Organ Dysfunction in Septic Shock Patients |
| NCT06626880 | Not specified | NOT_YET_RECRUITING | Predictive Value of Scoring System in Neonates with Disseminated Intravascular Coagulation |
| NCT06727669 | Not specified | RECRUITING | Longitudinal Cohort of Thrombosis and Hemostasis Diseases |
| NCT06765681 | Not specified | ACTIVE_NOT_RECRUITING | An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related |
| NCT07234630 | Not specified | NOT_YET_RECRUITING | Role of Fibrinolytic Activity in Neoplastic Pathologies Complicated by Coagulopathy |
| NCT07585942 | Not specified | NOT_YET_RECRUITING | Fluorescent Leukocytes as a Marker of Early Sepsis/Severity |
| NCT00299949 | Not specified | TERMINATED | Thrombin Generation and Thromboelastography in Non-overt DIC |
| NCT03577015 | Not specified | UNKNOWN | International Prospective Registry of Disseminated Intravascular Coagulation |
| NCT03714048 | Not specified | COMPLETED | Blood Management During ECMO for Cardiac Support |
| NCT03716310 | Not specified | COMPLETED | Platelet Reactivity in Septic Shock |
| NCT04107402 | Not specified | COMPLETED | PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock |
| NCT04356144 | Not specified | COMPLETED | Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections |
| NCT04356950 | Not specified | COMPLETED | Analysis of the Coagulopathy Developed by COVID-19 Infected Patients |
| NCT04460664 | Not specified | COMPLETED | Coagulation Changes Associated With COVID-19 Infection |
| NCT04580563 | Not specified | COMPLETED | Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study |
| NCT04873349 | Not specified | COMPLETED | Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients |
| NCT05995093 | Not specified | UNKNOWN | The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation |
| NCT06373159 | Not specified | COMPLETED | An Observational Study to Learn About the Occurrence of Disseminated Intravascular Coagulation Among Adults With Sepsis in Japan |
| NCT06860503 | Not specified | COMPLETED | Thrombelastography for Coagulopathy in Chinese Snakebites |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ANTITHROMBIN ALFA | 4 | 3 |
| HEPARIN SODIUM | 4 | 1 |
| SODIUM CHLORIDE | 4 | 1 |
| THROMBOMODULIN ALFA | 3 | 2 |
| ANTITHROMBIN III HUMAN | 3 | 1 |